News Daily News Patients With Obesity Get Biggest Benefit from Evolocumab: FOURIER Michael O'Riordan December 12, 2025
News Opinion Editor's Corner TCTMD’s Top 10 Most Popular Stories for November 2025 Caitlin E. Cox December 01, 2025
News Daily News Dig Deeper When Dealing With Nonobstructive CAD, AHA Urges Caitlin E. Cox November 21, 2025
News Conference News AHA 2025 CRISPR-Cas9 Gene-Editing Therapy Shows Early Promise for Dyslipidemia Todd Neale November 08, 2025
News Opinion Editor's Corner AHA 2025 What’s Going to Be Hot at AHA 2025? Michael O'Riordan November 05, 2025
News Opinion CV Team Dispatch September 2025 Dispatch for the CV Team L.A. McKeown September 30, 2025
News Conference News ESC 2025 NEWTON-CABG CardioLink-5: Evolocumab Doesn’t Prevent SVG Failure Michael O'Riordan September 04, 2025
News Daily News Evolocumab Gains Expanded Indication for Primary Prevention Michael O'Riordan August 26, 2025
News Opinion Editor's Corner ESC 2025 What’s Going to Be Hot at ESC Congress 2025? Michael O'Riordan August 25, 2025
News Daily News Inclisiran Gains Indication as Stand-alone Therapy to Reduce LDL Cholesterol Michael O'Riordan August 06, 2025
News Daily News No Clarity on Colchicine: Two Meta-analyses Spark Debate on Drug’s Merits Michael O'Riordan July 14, 2025
News Daily News Inclisiran Plus Usual Care Improves LDL Control in ACS: VICTORION-INCEPTION Michael O'Riordan June 04, 2025
News Daily News Early Combo Therapy With Ezetimibe Lowers MACE Risk After MI Michael O'Riordan April 22, 2025
News Conference News ACC 2025 SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes Michael O'Riordan March 29, 2025
News Daily News Elderly ASCVD Patients Benefit From Aggressive LDL-Lowering With Evolocumab Michael O'Riordan February 05, 2025
News Conference News AHA 2024 ZODIAC: Decision-Support Tool Doesn’t Sway Lipid-Lowering Treatments in ACS Michael O'Riordan November 21, 2024
News Conference News AHA 2024 Two Lp(a)-Lowering Therapies Clear Bar in KRAKEN and ALPACAR-360 Michael O'Riordan November 18, 2024
Presentation TCT 2024 Changes in Plaque Volume and Plaque Composition After 12 Weeks of Extensive LDL-C Reduction With PCSK9 Inhibitors in ACS Patients With Multivessel Disease Presenter: Jonathan Los October 27, 2024
News Daily News Lp(a) Levels, Still Mostly Genetic, Sometimes Vary Over a Lifetime Michael O'Riordan October 14, 2024
News Conference News ESC 2024 Getting to Cholesterol Goal Early After MI Lowers Risk of Recurrent Events Michael O'Riordan September 01, 2024